Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The beneficial effects of SGLT2 inhibitors on the conventional risk factors for kidney disease (such as blood pressure, hyperglycaemia, body weight and serum uric acid levels) may explain, at least in part, the observed renal-protecting properties of these compounds.
|
27748201 |
2017 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT-2 inhibitors have been shown to reduce glycated hemoglobin (A1C), weight, and blood pressure, which not only affects glycemic control, but may also help slow the progression of renal disease by impacting the underlying mechanisms of kidney injury.
|
27977314 |
2017 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
There is a possibility that SGLT-2 inhibition may correct hyperfiltration in diabetes, adding a new therapeutic approach to halt renal disease in patients with diabetes.
|
27978521 |
2017 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, our study showed that SGLT2 inhibition modulates renal lipid metabolism and inflammation and prevents the development of nephropathy in db/db mice.
|
28196866 |
2017 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease.
|
28482281 |
2017 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings demonstrate that SGLT2 inhibitors alleviate various diabetic pathological conditions in type 2 diabetic mice, and suggest that SGLT2 inhibitors, particularly long-acting drugs, might be useful not only for hyperglycemia but also in diabetes-related diseases and complications, including nephropathy in type 2 diabetes.
|
28506912 |
2017 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Beneficial effects on kidney disease progression, cardiovascular and all-cause mortality, and hospitalization for heart failure have also been demonstrated with one SGLT2 inhibitor (empagliflozin).
|
28721687 |
2017 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Several ongoing clinical trials are in the planning stages to evaluate SGLT-2 inhibition in a population of patients with overt kidney disease.
|
28743130 |
2017 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, the treatment of diabetes mellitus using SGLT2 inhibitors could be one of the effective approach for the management of diabetic-associated kidney disease like DN.
|
28759755 |
2017 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent randomized clinical trials in high cardiovascular risk patients with type 2 diabetes suggest that the unique effects of SGLT2 inhibitors on blood pressure and body weight may translate into reduced cardiovascular events and slowed kidney disease progression.
|
29349558 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, SGLT2 inhibitors could constitute a novel therapeutic target for the treatment of type 2 diabetes with overt nephropathy.
|
29374293 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, SGLT2 inhibition prevents further renal function deterioration and death from kidney disease in these patients.
|
29482993 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Sodium glucose co-transporter 2 (SGLT2) inhibitors appear to protect against increased risks of cardiovascular and kidney disease in patients with type 2 diabetes but also cause some harms.
|
29604389 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that the SGLT2 inhibitor ipragliflozin prevents progression to diabetic overt nephropathy in uninephrectomized type 2 diabetic mice.
|
29702076 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our aim is to review the rationale for renal protection with SGLT2 inhibitors, and their current place in the clinical management of patients with kidney disease.
|
29735306 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The renoprotective action of SGLT-2 inhibitors is strongly supported by human studies showing that these agents prevent the progression of albuminuria and retard nephropathy progression to ESRD.
|
29792136 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Available English-language data from reviews, abstracts, presentations, and clinical trials of use of SGLT2 therapy specifically detailing outcomes on CV and renal disease in humans were reviewed.
|
29911393 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Since hyperglycemia contributes to arterial stiffness, we hypothesized that the SGLT2 inhibitor empagliflozin (EMPA) would improve endothelial function, reduce aortic stiffness, and attenuate kidney disease by lowering hyperglycemia in type 2 diabetic female mice (db/db).
|
30060748 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.
|
30089717 |
2018 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
|
30929540 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review considers anew the etiology of the cardio-renal protective effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors by extending the discussion to renal congestion, inherent in diabetic kidney disease (DKD) even at an early stage of nephropathy in which heart failure (HF) or salt and water accumulation is asymptomatic.
|
31291624 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
|
31310751 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have important cardiovascular and renal benefits in adults with type 2 diabetes who have or are at high risk of cardiovascular and renal disease.
|
31377891 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, there is growing evidence to illustrate the overall safety profile of this class of agents and support the benefit-risk profile of SGLT2 inhibitors as a preferred option following metformin monotherapy failure, with respect to both kidney disease progression and heart failure outcomes.
|
31410711 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular safety, have revealed that these medications have a preventative advantage on adverse cardiovascular outcomes, including worsening of heart failure and deterioration of nephropathy, in patients with type 2 diabetes (T2D).
|
31440988 |
2019 |